Insulet CorporationPODDEarnings & Financial Report
An insulin pump is a medical device used for the administration of insulin in the treatment of diabetes mellitus, also known as continuous subcutaneous insulin therapy . The device configuration may vary depending on design. A traditional pump includes:the pump a disposable reservoir for insulin a disposable infusion set, including a cannula for subcutaneous insertion and a tubing system to connect the insulin reservoir to the cannula.
Revenue
$488.5M
Gross Profit
$330.9M
Operating Profit
$54.6M
Net Profit
$188.6M
Gross Margin
67.7%
Operating Margin
11.2%
Net Margin
38.6%
YoY Growth
23.2%
EPS
$2.59
Insulet Corporation Q2 FY2024 Financial Summary
Insulet Corporation reported revenue of $488.5M (up 23.2% YoY) for Q2 FY2024, with a net profit of $188.6M (up 590.8% YoY) (38.6% margin). Cost of goods sold was $157.6M, operating expenses totaled $276.3M.
Key Financial Metrics
| Total Revenue | $488.5M |
|---|---|
| Net Profit | $188.6M |
| Gross Margin | 67.7% |
| Operating Margin | 11.2% |
| Report Period | Q2 FY2024 |
Revenue Breakdown
Insulet Corporation Q2 FY2024 revenue of $488.5M breaks down across 3 segments, led by U.S.Omnipod at $352.3M (72.1% of total).
| Segment | Revenue | % of Total |
|---|---|---|
| U.S.Omnipod | $352.3M | 72.1% |
| International Omnipod | $128.1M | 26.2% |
| Drug Delivery | $8.1M | 1.7% |
Insulet Corporation Revenue by Segment — Quarterly Trend
Insulet Corporation revenue by segment across the last 4 reported quarters, showing how each business line (such as U.S.Omnipod and International Omnipod) has evolved quarter over quarter.
| Segment | Q1 FY2026 | Q4 FY2025 | Q3 FY2025 | Q2 FY2025 |
|---|---|---|---|---|
| U.S.Omnipod | — | $567.8M | — | $453.2M |
| International Omnipod | $242.9M | $214.0M | — | $185.8M |
| Drug Delivery | $3.3M | $1.9M | $7.1M | $10.2M |
Insulet Corporation Annual Revenue by Year
Insulet Corporation annual revenue history includes year-by-year totals (for example, 2025 revenue was $2.7B).
| Year | Annual Revenue |
|---|---|
| 2025 | $2.7B |
| 2024 | $2.1B |
Insulet Corporation Quarterly Revenue & Net Profit History
Insulet Corporation results over the last 8 reported quarters, including revenue, net profit and year-over-year growth.
| Quarter | Revenue | Revenue YoY | Net Profit | Net Margin |
|---|---|---|---|---|
| Q1 FY2026 | $761.7M | +33.9% | $91.1M | 12.0% |
| Q4 FY2025 | $783.7M | +31.2% | $101.6M | 13.0% |
| Q3 FY2025 | $706.3M | +29.9% | $87.6M | 12.4% |
| Q2 FY2025 | $649.1M | +32.9% | $22.5M | 3.5% |
| Q1 FY2025 | $569.0M | +28.8% | $35.4M | 6.2% |
| Q4 FY2024 | $597.5M | +17.2% | $100.7M | 16.9% |
| Q3 FY2024 | $543.9M | +25.7% | $77.5M | 14.2% |
| Q2 FY2024 | $488.5M | +23.2% | $188.6M | 38.6% |
Income Statement
| Q2 2024 | Q3 2024 | Q4 2024 | Q1 2025 | Q2 2025 | Q3 2025 | Q4 2025 | Q1 2026 | |
|---|---|---|---|---|---|---|---|---|
| Revenue | $488.5M | $543.9M | $597.5M | $569.0M | $649.1M | $706.3M | $783.7M | $761.7M |
| YoY Growth | 23.2% | 25.7% | 17.2% | 28.8% | 32.9% | 29.9% | 31.2% | 33.9% |
Balance Sheet
| Q2 2024 | Q3 2024 | Q4 2024 | Q1 2025 | Q2 2025 | Q3 2025 | Q4 2025 | Q1 2026 | |
|---|---|---|---|---|---|---|---|---|
| Assets | $2.88B | $3.03B | $3.09B | $3.52B | $3.47B | $3.03B | $3.19B | $2.99B |
| Liabilities | $1.88B | $1.91B | $1.88B | $2.19B | $2.01B | $1.65B | $1.68B | $1.68B |
| Equity | $998.4M | $1.12B | $1.21B | $1.33B | $1.46B | $1.38B | $1.52B | $1.30B |
Cash Flow
| Q2 2024 | Q3 2024 | Q4 2024 | Q1 2025 | Q2 2025 | Q3 2025 | Q4 2025 | Q1 2026 | |
|---|---|---|---|---|---|---|---|---|
| Operating CF | $96.5M | $98.5M | $147.7M | $63.8M | $196.5M | $125.7M | $183.3M | $113.8M |